Hematopoietic stem cell transplantation and implications for cell therapy reimbursement

Richard T. Maziarz, Dawn Driscoll

Research output: Contribution to journalComment/debate

9 Scopus citations


As costly stem cell treatments progress from experimental concepts toward licensed products and routine procedures, governmental and private payers grapple with shrinking budgets to cover more lives. We describe efforts underway in the US to create mechanisms for reimbursement of cell therapies and discuss other reimbursement-related issues for the stem cell community.

Original languageEnglish (US)
Pages (from-to)609-612
Number of pages4
JournalCell Stem Cell
Issue number6
StatePublished - Jun 3 2011


ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cell Biology

Cite this